Sandoz recalls losartan products

The first of a series of recalls involving blood pressure medication were in August. Months later, tainted drugs continue to be found in the US supply. The FDA and Sandoz have announced the recall of one lot of losartain blood pressure medicine that was manufactured by its Lek Pharmaceuticals unit in Ljubljana, Slovenia, because it contains N-nitrosodiethylamine (NDEA), a suspected carcinogen.

NDEA along with N-Nitrosodimethylamine (NDMA) are two probable human carcinogens that the FDA has discovered can be created during manufacturing under certain conditions.

Click here to view the entire article.